Tofacitinib is marketed under the brand name Xeljanz [1].
What is Xeljanz used for?
Xeljanz is approved for treating adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1]. It is also used for polyarticular course juvenile idiopathic arthritis in patients two years of age and older [1].
How does Xeljanz work?
Tofacitinib is a Janus kinase (JAK) inhibitor. It works by blocking the activity of certain enzymes, called JAKs, which are involved in the signaling pathways that cause inflammation and immune responses [1].
When does the Xeljanz patent expire?
Patent exclusivity for Xeljanz is a complex issue with multiple patents covering different aspects of the drug, including formulation and manufacturing [2]. Information regarding specific patent expiry dates and potential challenges can be found on resources like DrugPatentWatch.com [2].
Can generic versions of Xeljanz be made?
The availability of generic versions of Xeljanz depends on patent expirations and potential legal challenges to those patents. Once patents expire and regulatory hurdles are cleared, generic manufacturers may be able to produce and market their versions of tofacitinib [2].
What are the potential side effects of Xeljanz?
Xeljanz carries a boxed warning regarding serious infections, including tuberculosis and invasive fungal infections, and the risk of death [1]. It can also increase the risk of blood clots, cancer, and heart attack or stroke. Other common side effects include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis [1].
How does Xeljanz compare to other arthritis treatments?
Xeljanz belongs to a class of drugs known as JAK inhibitors. Other JAK inhibitors used for similar conditions include baricitinib (Olumiant) and upadacitinib (Rinvoq) [3]. These medications work by targeting inflammation pathways, offering an alternative to traditional disease-modifying antirheumatic drugs (DMARDs) and biologic therapies [3].
What is the clinical data supporting Xeljanz?
Clinical trials have demonstrated Xeljanz's efficacy in reducing signs and symptoms of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, and in improving physical function [1].
Who manufactures Xeljanz?
Xeljanz is manufactured by Pfizer [1].
What are the risks associated with Xeljanz treatment?
Patients taking Xeljanz should be monitored for signs of serious infections, cardiovascular events, and the development of malignancies [1]. Regular blood tests are often required to check for potential side effects [1].
---
Sources:
[1] Xeljanz Official Website
[2] DrugPatentWatch.com
[3] National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)